Sex Differences in Anesthesiology: A Comprehensive Overview
Significant sex differences exist across multiple domains of anesthesiology, including anesthetic sensitivity, drug pharmacokinetics/pharmacodynamics, pain perception, cardiovascular disease presentation, and clinical outcomes—yet women remain critically underrepresented in research, comprising less than 30% of clinical trial participants 1, 2.
Anesthetic Sensitivity and Emergence
Females demonstrate greater resistance to volatile anesthetics than males at identical brain concentrations, recovering consciousness and cognition faster after anesthesia 3. This sex difference is:
- Hormonally mediated: Testosterone bidirectionally modulates anesthetic sensitivity. Castration increases resistance, while testosterone administration acutely increases sensitivity. Aromatase conversion of testosterone to estradiol partially explains this effect 3.
- Evolutionarily conserved: The same pattern exists in both mice and humans 3.
- Not reflected in EEG monitoring: Conventional electroencephalographic measures fail to capture these sex differences, which may explain why females experience higher rates of unintended intraoperative awareness 3.
- Neuroanatomically distinct: Under anesthesia, females show fewer active neurons in ventral hypothalamic sleep-promoting regions compared to males 3.
Drug-Specific Pharmacological Differences
Propofol
- Women exhibit reduced sensitivity to propofol but experience more rapid emergence from general anesthesia 4.
Opioids
- Women demonstrate increased sensitivity to opioids 4.
- Despite experiencing more severe postoperative pain, female patients historically receive less opioid analgesia than males—though recent data suggest this disparity may be team-dependent 5.
Neuromuscular Blockers
- Women show increased sensitivity to rocuronium 4.
Remimazolam
- Serum concentrations are significantly lower in females at both end-of-administration and pre-extubation timepoints, suggesting more rapid metabolism in women 6.
- Despite pharmacokinetic differences, emergence times remain similar between sexes when combined with remifentanil 6.
Dexmedetomidine
- No clinically meaningful sex difference exists in the median effective dose (ED50) for preoperative sedation: 1.26 μg/kg in men versus 1.28 μg/kg in women 7.
- Sex-based dose adjustment is not supported for preoperative sedation in healthy adults 7.
Pain and Postoperative Outcomes
Women experience more severe acute and chronic postoperative pain 4, yet paradoxically exhibit lower mortality rates postoperatively 4. Key considerations:
- Pain management disparities exist: All-female anesthesia teams administered more opioids to female patients compared to all-male or mixed teams, suggesting potential gender bias in pain assessment 5.
- Weight-adjusted opioid doses and pain scores were comparable between sexes in thoracic surgery when properly assessed 5.
- Complication profiles vary by both sex and surgical type 4.
Cardiovascular Disease Considerations
Cardiovascular disease remains the leading cause of death in women globally, yet is understudied, underdiagnosed, and undertreated 1. Critical perioperative implications:
- Women present with different disease entities: spontaneous coronary artery dissection and microvascular dysfunction are more common in females 1.
- Delays in diagnosis and less aggressive treatment persist 1.
- Pregnancy-related cardiovascular complications are rapidly rising and require specialized risk assessment 1.
- Sex-disaggregated diagnostic and management strategies are not currently recommended in clinical guidelines despite growing evidence 1.
Research and Clinical Practice Gaps
Critical Deficiencies
- Women comprise <30% of clinical trial participants 1.
- Preclinical studies predominantly use male animals [@10@, referenced in 1].
- Pregnant and breastfeeding women are routinely excluded from research 1.
- Sex is rarely analyzed as a biological variable in anesthesia research 2.
Methodological Recommendations
The SmartTots Preclinical Working Group recommends 2:
- Animals of both sexes should be included in studies.
- Sex distribution must be reported and analyzed as a biological variable.
- Strong justification is required for single-sex studies.
- Within anesthetic neurotoxicity research, sex has emerged as an important variable with distinct behavioral and neurochemical responses between males and females.
Clinical Implications
Preoperative risk assessment should incorporate sex-specific considerations 4, 8:
- Recognize that conventional anesthetic depth monitoring (EEG/BIS) may not accurately reflect anesthetic state in females 3.
- Anticipate faster emergence in females despite similar drug dosing 3, 4.
- Adjust opioid and neuromuscular blocker dosing based on increased female sensitivity 4.
- Implement more aggressive postoperative pain management protocols for female patients 4.
- Consider sex-specific cardiovascular risk profiles, particularly in pregnant patients 1.
Special Populations
Transgender patients represent a vulnerable population requiring specialized perioperative care 8, though specific evidence-based protocols remain underdeveloped.
Common Pitfalls
- Assuming EEG-based depth monitoring is equally valid across sexes—it systematically underestimates anesthetic resistance in females 3.
- Underdosing opioids in female patients based on historical bias rather than their demonstrated increased sensitivity 4, 5.
- Applying male-derived research findings universally when sex-specific mechanisms differ substantially 1, 9.
- Ignoring hormonal status when assessing anesthetic requirements, particularly testosterone levels 3.
The evidence consistently demonstrates that sex is a fundamental biological variable affecting virtually every aspect of anesthetic care, yet clinical practice and research design have failed to adequately account for these differences 8, 9. This knowledge gap directly compromises patient safety and outcomes, particularly for female patients 1, 3.